Daptomycin (Daptomycin) Patent Expiration, LOE Window & CMS Spending

Daptomycin (Daptomycin) by Sagent: FDA Orange Book LOE 2043-01-09, 23 AB generics, $152.4M 2024 CMS Part D & Medicaid spend, and $4,450 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSagent
FDA Application & PathwayN208385 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2043-01-09
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors23
2024 CMS Total Public Spend$152.4M
2024 Medicare Part D Spend$120.7M
2024 Medicaid Spend$31.8M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($4,450 intro WAC)